echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > $234 million!

    $234 million!

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 8, Hansoh Pharma announced that its wholly-owned subsidiaries Hansson (Shanghai) Health Technology .


    Under the license agreement, the licensee received an exclusive license from TiumBio to develop and commercialize TU2670 for the treatment of endometriosis and uterine fibroids and other potential indications in China, including Hong Kong, Macau and Taiw.


    $5 million down payment, $5 million in technology transfer fees and potential payments of up to $164 million in development, registration and sales-based commercialization milestones

    Endometriosis refers to the endometrial cells that should grow in the uterine cavi.


    Uterine fibroids are a common benign tumor that occurs in the uterus, often accompanied by symptoms such as pain, menorrhagia, dysfunctional uterine bleeding, and urinary incontinence, with an incidence of about 3


    TU2670 is an orally active non-peptide gonadotropin-releasing hormone (GnRH) antagonist independently developed by Tiumbio, which can bind to pituitary receptors to inhibit the secretion of gonadotropins (luteinizing hormone and follicle-stimulating hormon.


    Currently, TU2670 has completed a Phase Ia clinical trial in South Korea and a Phase Ib clinical trial in Europe (German.


    Headquartered in South Korea, TiumBio is an R&D-focused biopharmaceutical company dedicated to the discovery and development of innovative small molecule and biopharmaceutica.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.